Common cholesterol pill may shield cancer Patients' hearing

NCT ID NCT04915183

Summary

This study is testing whether atorvastatin, a common cholesterol-lowering drug, can prevent hearing loss caused by cisplatin chemotherapy. Researchers are enrolling 224 adults with head and neck cancer who will receive cisplatin and radiation. Participants will be randomly assigned to take either atorvastatin or a placebo pill daily during and after their cancer treatment to see if the drug protects their hearing.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEARING LOSS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Inova Schar Cancer Center

    RECRUITING

    Fairfax, Virginia, 22031, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • National Institutes of Health Clinical Center

    RECRUITING

    Bethesda, Maryland, 20892, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Maryland Medical Center

    NOT_YET_RECRUITING

    Baltimore, Maryland, 21201, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Wilmot Cancer Institute at the University of Rochester Medical Center in New Yor

    NOT_YET_RECRUITING

    Rochester, New York, 14642, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Winship Cancer Institute at Emory University

    NOT_YET_RECRUITING

    Atlanta, Georgia, 30322, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.